Page last updated: 2024-12-07

cv 3988

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

CV 3988: platelet activating factor antagonist; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID107681
CHEMBL ID295212
SCHEMBL ID8701203
MeSH IDM0114418

Synonyms (39)

Synonym
cv-3988
EU-0101060
3-motp
2-methoxy-3-(octadecylcarbamoyloxy)propyl-2-(3-thiazolinium) ethyl phosphate
cv 3988
thiazolium, 3-(4-hydroxy-7-methoxy-10-oxo-3,5,9-trioxa-11-aza-4-phosphanonacos-1-yl)-, inner salt
thiazolium, 3-(4-hydroxy-7-methoxy-10-oxo-3,5,9-trioxa-11-aza-4-phosphanonacos-1-yl)-, hydroxide, inner salt, p-oxide, (+-)-
3-(n-n-octadecylcarbamoyloxy)-2-methoxypropyl-2-thiazolinium ethyl phosphate
NCGC00094342-01
NCGC00162331-01
NCGC00015263-02
(+/-)-(3-(n-octadecylcarbamoyloxy)-2-methoxy)propyl-2-thiazolioethyl phosphate
C 7238
NCGC00015263-04
CHEMBL295212 ,
85703-73-7
92203-21-9
3-{2-[hydroxy-(2-methoxy-3-octadecylcarbamoyloxy-propoxy)-phosphoryloxy]-ethyl}-thiazol-3-ium(cv-3988)
2-methoxy-3-(octadecylcarbamoyloxy)propyl 2-(thiazol-3-ium-3-yl)ethyl phosphate
octadecyl-carbamic acid 3-[hydroxy-(2-thiazol-3-yl-ethoxy)-phosphorylo xy]-2-methoxy-propyl ester(cv-3988)
3-{2-[hydroxy-(2-methoxy-3-octadecylcarbamoyloxy-propoxy)-phosphoryloxy]-ethyl}-thiazol-3-ium
bdbm50006048
3-{2-[(2-methoxy-3-octadecylcarbamoyloxy-propoxy)-phosphonooxy-methoxy]-ethyl}-thiazol-3-ium
[2-methoxy-3-(octadecylcarbamoyloxy)propyl] 2-(1,3-thiazol-3-ium-3-yl)ethyl phosphate
cv3988
CCG-205137
NCGC00015263-03
cv-3988 hydrate
LP01060
gtpl6079
SCHEMBL8701203
DTXSID40276040
Q27076930
SDCCGSBI-0051030.P002
3-[hydroxy(octadecylimino)methoxy]-2-methoxypropyl 2-(1,3-thiazol-3-ium-3-yl)ethyl phosphate
DTXSID701006301
GLXC-26218
2-methoxy-3-((octadecylcarbamoyl)oxy)propyl (2-(thiazol-3-ium-3-yl)ethyl) phosphate
AKOS040748197

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Pretreatment with CV 3988 attenuated systemic hypotension, preserved hypoxic pulmonary vasoconstriction, and prolonged survival of awake catheter-implanted endotoxin-treated (20 mg/kg) rats."( Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats.
Chang, SW; Feddersen, CO; Henson, PM; Voelkel, NF, 1987
)
0.6

Dosage Studied

ExcerptRelevanceReference
" The amount of dye extracted from the paw showed a clear dose-response relationship to the dose of each agonist injected into the paw."( Assessment of vascular permeability increase in the mouse by dye leakage during paw edema.
Hayashi, M; Oh-ishi, S; Qu, XF; Yamaki, K, 1990
)
0.28
" The inhibition was shown to be specific and competitive with PAF on its receptor by the following observations: parallel shift of the dose-response curve; crossing of double reciprocal plots on the intersection of the ordinate; and no inhibition on other autacoids such as bradykinin, histamine, 5-hydroxytryptamine and LTC4."( Characterization of the activity of a platelet activating factor antagonist, CV-3988.
Hayashi, M; Kimura, J; Nomura, H; Oh-Ishi, S; Tsushima, S, 1987
)
0.27
"Platelet-activating factor (PAF), 1-o-alkyl-2-acetyl-sn-glyceryl-3-phosphoryl choline, induced acute bronchoconstriction in the guinea pig when intravenously administered in a very small dosage (30 ng/kg)."( Bronchoconstriction induced by platelet-activating factor in the guinea pig and its inhibition by CV-3988, a PAF antagonist: serial changes in findings of lung histology and bronchoalveolar lavage cell population.
Ishii, A; Miyamoto, T; Shiga, J; Suzuki, S; Takizawa, H, 1988
)
0.27
" In mouse models of anaphylaxis, one of the peptides, BP21, markedly and dose-dependently inhibited hypothermia with a maximum dose-response within 30 min after administration, even at doses 20 times lesser than doses of the known PAF antagonist CV-3988."( A biotinylated peptide, BP21, as a novel potent anti-anaphylactic agent targeting platelet-activating factor.
Ebina, K; Sato, A, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.89130.003245.467312,589.2998AID2517
Chain A, Ferritin light chainEquus caballus (horse)Potency39.81075.623417.292931.6228AID2323
Chain A, CruzipainTrypanosoma cruziPotency31.62280.002014.677939.8107AID1476
thioredoxin reductaseRattus norvegicus (Norway rat)Potency9.29090.100020.879379.4328AID488773; AID588453; AID588456
USP1 protein, partialHomo sapiens (human)Potency19.95260.031637.5844354.8130AID504865
regulator of G-protein signaling 4Homo sapiens (human)Potency5.96710.531815.435837.6858AID504845
arylsulfatase AHomo sapiens (human)Potency6.01201.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency50.31260.035520.977089.1251AID504332
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)Homo sapiens (human)Potency18.49270.016525.307841.3999AID602332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency35.48130.540617.639296.1227AID2364; AID2528
ubiquitin carboxyl-terminal hydrolase 2 isoform aHomo sapiens (human)Potency14.68920.65619.452025.1189AID463106
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency24.70120.00378.618923.2809AID2660; AID2666
gemininHomo sapiens (human)Potency27.51490.004611.374133.4983AID463097; AID504364
lamin isoform A-delta10Homo sapiens (human)Potency22.53580.891312.067628.1838AID1459; AID1487
Alpha-synucleinHomo sapiens (human)Potency29.09290.56239.398525.1189AID652106
Ataxin-2Homo sapiens (human)Potency28.18380.011912.222168.7989AID588378
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.03790.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Platelet-activating factor receptorCavia porcellus (domestic guinea pig)IC50 (µMol)7.80000.00430.75777.8000AID167655
Platelet-activating factor receptorHomo sapiens (human)IC50 (µMol)0.60000.00030.63183.7000AID161575
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (111)

Processvia Protein(s)Taxonomy
positive regulation of cellular extravasationPlatelet-activating factor receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIPlatelet-activating factor receptorHomo sapiens (human)
chemotaxisPlatelet-activating factor receptorHomo sapiens (human)
inflammatory responsePlatelet-activating factor receptorHomo sapiens (human)
immune responsePlatelet-activating factor receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayPlatelet-activating factor receptorHomo sapiens (human)
parturitionPlatelet-activating factor receptorHomo sapiens (human)
response to symbiotic bacteriumPlatelet-activating factor receptorHomo sapiens (human)
lipopolysaccharide-mediated signaling pathwayPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of interleukin-6 productionPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of tumor necrosis factor productionPlatelet-activating factor receptorHomo sapiens (human)
inositol trisphosphate biosynthetic processPlatelet-activating factor receptorHomo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathwayPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of neutrophil degranulationPlatelet-activating factor receptorHomo sapiens (human)
transcytosisPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of translationPlatelet-activating factor receptorHomo sapiens (human)
negative regulation of blood pressurePlatelet-activating factor receptorHomo sapiens (human)
positive regulation of smooth muscle cell proliferationPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processPlatelet-activating factor receptorHomo sapiens (human)
cellular response to gravityPlatelet-activating factor receptorHomo sapiens (human)
cellular response to cAMPPlatelet-activating factor receptorHomo sapiens (human)
cellular response to fatty acidPlatelet-activating factor receptorHomo sapiens (human)
response to dexamethasonePlatelet-activating factor receptorHomo sapiens (human)
positive regulation of leukocyte tethering or rollingPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of transcytosisPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of maternal process involved in parturitionPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of gastro-intestinal system smooth muscle contractionPlatelet-activating factor receptorHomo sapiens (human)
cellular response to 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholinePlatelet-activating factor receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayPlatelet-activating factor receptorHomo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (35)

Processvia Protein(s)Taxonomy
lipopolysaccharide bindingPlatelet-activating factor receptorHomo sapiens (human)
lipopolysaccharide immune receptor activityPlatelet-activating factor receptorHomo sapiens (human)
G protein-coupled receptor activityPlatelet-activating factor receptorHomo sapiens (human)
platelet activating factor receptor activityPlatelet-activating factor receptorHomo sapiens (human)
protein bindingPlatelet-activating factor receptorHomo sapiens (human)
phospholipid bindingPlatelet-activating factor receptorHomo sapiens (human)
mitogen-activated protein kinase bindingPlatelet-activating factor receptorHomo sapiens (human)
G protein-coupled purinergic nucleotide receptor activityPlatelet-activating factor receptorHomo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (28)

Processvia Protein(s)Taxonomy
plasma membranePlatelet-activating factor receptorHomo sapiens (human)
membranePlatelet-activating factor receptorHomo sapiens (human)
secretory granule membranePlatelet-activating factor receptorHomo sapiens (human)
tertiary granule membranePlatelet-activating factor receptorHomo sapiens (human)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (38)

Assay IDTitleYearJournalArticle
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID76615In vivo activity for protection against PAF acether induced bronchoconstriction in guinea pig after 5 min of intravenous administration (2 mg/kg)1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Structure-activity relationship in PAF-acether. 4. Synthesis and biological activities of carboxylate isosteres.
AID167655Inhibition of rabbit platelet aggregation induced by platelet activating factor (PAF)1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Platelet activating factor antagonists: synthesis and structure-activity studies of novel PAF analogues modified in the phosphorylcholine moiety.
AID1064257Antiplatelet activity against New Zealand white rabbit platelets assessed as inhibition of PAF-induced platelet aggregation preincubated at 10 uM for 2 mins before challenge measured after 2 mins by spectrophotometry2014Journal of natural products, Jan-24, Volume: 77, Issue:1
Lignans from the aerial parts of Saururus chinensis: isolation, structural characterization, and their effects on platelet aggregation.
AID161575Ability to inhibit platelet activating factor (PAF) binding to platelets by 50% was determined by using [3H]PAF as radioligand1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Pyrido[2,1-b]quinazolinecarboxamide derivatives as platelet activating factor antagonists.
AID188686In vivo activity for protection against acetylcholine induced hypotension in rat after 5 mins of intravenous administration (1 mg/kg)1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Structure-activity relationship in PAF-acether. 4. Synthesis and biological activities of carboxylate isosteres.
AID167463In vivo antagonistic activity against platelet aggregation1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Structure-activity relationship in PAF-acether. 4. Synthesis and biological activities of carboxylate isosteres.
AID224348Inhibition of PAF-induced platelet aggregation in rabbit platelet rich plasma1993Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5
Analogues of platelet activating factor. 8. Antagonists of PAF containing an aromatic ring linked to a pyridinium ring.
AID1331283Antiplatelet aggregatory activity against New Zealand white rabbit platelets at 10 uM preincubated for 2 to 3 mins followed by PAF-addition measured after 4 mins by turbidometric method relative to vehicle control2017Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
Bioactive chemical constituents from the root bark of Morus australis.
AID76613In vivo activity for protection against PAF acether induced bronchoconstriction in guinea pig after 5 min of intravenous administration (0.5 mg/kg)1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Structure-activity relationship in PAF-acether. 4. Synthesis and biological activities of carboxylate isosteres.
AID354590Antiplatelet activity against rabbit platelet assessed as inhibition of platelet-activating factor-induced platelet aggregation preincubated for 3 mins by turbidimetric method1996Journal of natural products, Jul, Volume: 59, Issue:7
Antiplatelet flavonoids from seeds of Psoralea corylifolia.
AID188683In vivo activity for protection against PAF acether induced hypotension in rat after 5 mins of intravenous administration (1 mg/kg)1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Structure-activity relationship in PAF-acether. 4. Synthesis and biological activities of carboxylate isosteres.
AID224483Compound was tested for protecting PAF-induced lethality in mouse at a dose of 1 mg/kg (Out of 12)1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Analogues of platelet activating factor. 6. Mono- and bis-aryl phosphate antagonists of platelet activating factor.
AID167798Concentration needed to inhibit PAF-induced platelet aggregation in rabbit PRP by 50%1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Analogues of platelet activating factor. 6. Mono- and bis-aryl phosphate antagonists of platelet activating factor.
AID76618In vivo activity for protection against PAF acether induced thrombocytopenia in guinea pig after 5 min of intravenous administration (2 mg/kg)1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Structure-activity relationship in PAF-acether. 4. Synthesis and biological activities of carboxylate isosteres.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID76617In vivo activity for protection against PAF acether induced thrombocytopenia in guinea pig after 5 min of intravenous administration (1 mg/kg)1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Structure-activity relationship in PAF-acether. 4. Synthesis and biological activities of carboxylate isosteres.
AID76614In vivo activity for protection against PAF acether induced bronchoconstriction in guinea pig after 5 min of intravenous administration (1 mg/kg)1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Structure-activity relationship in PAF-acether. 4. Synthesis and biological activities of carboxylate isosteres.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID76616In vivo activity for protection against PAF acether induced thrombocytopenia in guinea pig after 5 min of intravenous administration (0.5 mg/kg)1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Structure-activity relationship in PAF-acether. 4. Synthesis and biological activities of carboxylate isosteres.
AID167299In vivo antagonistic activity against PAF induced platelet aggregation (5 x 10e-8 M )1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Structure-activity relationship in PAF-acether. 4. Synthesis and biological activities of carboxylate isosteres.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID167437In vivo antagonistic activity against collagen induced platelet aggregation (40 ug/mL)1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Structure-activity relationship in PAF-acether. 4. Synthesis and biological activities of carboxylate isosteres.
AID1346403Human PAF receptor (Platelet-activating factor receptor)1985Biochemical pharmacology, May-01, Volume: 34, Issue:9
Inhibition by CV-3988 of the binding of [3H]-platelet activating factor (PAF) to the platelet.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (207)

TimeframeStudies, This Drug (%)All Drugs %
pre-199082 (39.61)18.7374
1990's89 (43.00)18.2507
2000's21 (10.14)29.6817
2010's12 (5.80)24.3611
2020's3 (1.45)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.62 (24.57)
Research Supply Index5.37 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index24.72 (26.88)
Search Engine Supply Index3.67 (0.95)

This Compound (17.62)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.94%)5.53%
Reviews1 (0.47%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other209 (98.58%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]